Pilot Study of Hypofractionated Stereotactic Radiosurgery After Surgery for Grade II or Recurrent Grade I Meningioma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of hypofractionated stereotactic radiosurgery in patients who have had surgery for grade II meningiomas or recurrent grade I meningiomas. This study aims to assess this specialized radiation treatment, which uses focused high-energy rays to target tumor cells, after surgical removal of these brain tumors. It also explores survival rates, quality of life, financial impact, and gathers genetic information related to meningioma. The treatment involves a course of hypofractionated stereotactic radiosurgery delivered once daily over five consecutive days, each session lasting 15 to 30 minutes, provided there is no disease progression or unacceptable side effects. Participants also undergo regular imaging tests, including magnetic resonance imaging MRI throughout the study and computed tomography CT scans as needed. After completing the treatment, participants are followed up at 3 and 6 months, then annually for up to three years. During the study, participants will have their safety monitored by tracking any adverse events for up to one year. Researchers will also evaluate tumor control and survival outcomes over three years, along with assessing quality of life, financial burden, and treatment regrets using standardized questionnaires. Imaging tests help monitor disease status, and participants overall health and function will be regularly assessed to understand the treatments impact over time.

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma